Literature DB >> 20047097

A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders.

Ping Chong Bee1, G G Gan, V S Nadarajan, N A Latiff, N Menaka.   

Abstract

The co-occurrence of JAK2 V617F mutation with BCR-ABL reciprocal translocation is uncommon. We report a 60-year-old man who initially presented with phenotype of polycythemia vera (PV), which evolved into chronic myeloid leukemia and back to PV once treatment with imatinib was commenced. JAK2 V617F mutation and BCR-ABL fusion transcripts were detected in the initial sample. However, JAK2 V617F alleles diminished when BCR-ABL mRNA burden increased and reappeared once the patient was commenced on imatinib. The dynamic interaction between JAK2 V617F and BCR-ABL implies that two independent clones exist with the JAK2 V617F clone only achieving clonal dominance when BCR-ABL positive clones are suppressed by imatinib.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20047097     DOI: 10.1007/s12185-009-0471-6

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  12 in total

1.  Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation.

Authors:  Kais Hussein; Oliver Bock; Anna Seegers; Michael Flasshove; Felicitas Henneke; Guntram Buesche; Hans Heinrich Kreipe
Journal:  Blood       Date:  2007-05-01       Impact factor: 22.113

2.  Insights into JAK2-V617F mutation in CML.

Authors:  Monica Bocchia; Alessandro M Vannucchi; Alessandro Gozzetti; Paola Guglielmelli; Giada Poli; Rosaria Crupi; Marzia Defina; Alberto Bosi; Lauria Francesco
Journal:  Lancet Oncol       Date:  2007-10       Impact factor: 41.316

3.  JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia.

Authors:  Alwin Krämer; Andreas Reiter; Jens Kruth; Philipp Erben; Andreas Hochhaus; Martin Müller; Nicholas C P Cross; Amy V Jones; Anthony D Ho; Manfred Hensel
Journal:  Lancet Oncol       Date:  2007-07       Impact factor: 41.316

4.  Simultaneous detection of JAK2 V617F mutation and Bcr-Abl translocation in a patient with chronic myelogenous leukemia.

Authors:  Monika Ribeiro Mello de Conchon; Juliana Lima Costa; Mafalda Megumi Yoshinaga Novaes; Pedro Enrique Dorlhiac-Llacer; Dalton de Alencar Fischer Chamone; Israel Bendit
Journal:  Int J Hematol       Date:  2008-07-16       Impact factor: 2.490

5.  BCR-ABL positive chronic myeloid leukemia with concurrent JAK2(V617F) positive myelodysplastic syndrome/myeloproliferative neoplasm (RARS-T).

Authors:  Stefan Gattenlohner; Hans-Ulrich Völker; Benjamin Etschmann; Hermann Einsele; Hans-Konrad Müller-Hermelink
Journal:  Am J Hematol       Date:  2009-05       Impact factor: 10.047

6.  Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.

Authors:  Ross L Levine; Martha Wadleigh; Jan Cools; Benjamin L Ebert; Gerlinde Wernig; Brian J P Huntly; Titus J Boggon; Iwona Wlodarska; Jennifer J Clark; Sandra Moore; Jennifer Adelsperger; Sumin Koo; Jeffrey C Lee; Stacey Gabriel; Thomas Mercher; Alan D'Andrea; Stefan Fröhling; Konstanze Döhner; Peter Marynen; Peter Vandenberghe; Ruben A Mesa; Ayalew Tefferi; James D Griffin; Michael J Eck; William R Sellers; Matthew Meyerson; Todd R Golub; Stephanie J Lee; D Gary Gilliland
Journal:  Cancer Cell       Date:  2005-04       Impact factor: 31.743

7.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

8.  Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.

Authors:  Animesh Pardanani; Brooke L Fridley; Terra L Lasho; D Gary Gilliland; Ayalew Tefferi
Journal:  Blood       Date:  2007-11-15       Impact factor: 22.113

9.  Emergence of therapy-unrelated CML on a background of BCR-ABL-negative JAK2V617F-positive chronic idiopathic myelofibrosis.

Authors:  Laurent Jallades; Sandrine Hayette; Isabelle Tigaud; Anna Johnston; Bertrand Coiffier; Jean-Pierre Magaud; Martine Ffrench
Journal:  Leuk Res       Date:  2008-04-29       Impact factor: 3.156

10.  JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.

Authors:  Linda M Scott; Wei Tong; Ross L Levine; Mike A Scott; Philip A Beer; Michael R Stratton; P Andrew Futreal; Wendy N Erber; Mary Frances McMullin; Claire N Harrison; Alan J Warren; D Gary Gilliland; Harvey F Lodish; Anthony R Green
Journal:  N Engl J Med       Date:  2007-02-01       Impact factor: 91.245

View more
  10 in total

Review 1.  JAK2 and genomic instability in the myeloproliferative neoplasms: a case of the chicken or the egg?

Authors:  Linda M Scott; Vivienne I Rebel
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

2.  Coexistence of JAK2V617F Mutation and BCR-ABL Translocation in a Pregnant Woman with Essential Thrombocythemia.

Authors:  You-Wen Qin; Yi-Ning Yang; Su Li; Chun Wang
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-11       Impact factor: 0.900

3.  Myeloproliferative neoplasms with concurrent BCR-ABL1 translocation and JAK2 V617F mutation: a multi-institutional study from the bone marrow pathology group.

Authors:  Craig R Soderquist; Mark D Ewalt; David R Czuchlewski; Julia T Geyer; Heesun J Rogers; Eric D Hsi; Sa A Wang; Carlos E Bueso-Ramos; Attilio Orazi; Daniel A Arber; Elizabeth O Hexner; Daria V Babushok; Adam Bagg
Journal:  Mod Pathol       Date:  2018-01-12       Impact factor: 7.842

4.  Concomitant presence of JAK2 V617F mutation and BCR-ABL translocation in a pregnant woman with polycythemia vera.

Authors:  Gholamreza Toogeh; Shirin Ferdowsi; Fatemeh Naadali; Kamran Alimoghaddam; Ardeshir Ghavamzadeh; Reza Shirkoohi; Seyed H Ghaffari
Journal:  Med Oncol       Date:  2010-05-25       Impact factor: 3.064

5.  Frequency of JAK2 V617F mutation in patients with Philadelphia positive Chronic Myeloid Leukemia in Pakistan.

Authors:  Najia Tabassum; Mohammed Saboor; Rubina Ghani; Moinuddin Moinuddin
Journal:  Pak J Med Sci       Date:  2014-01       Impact factor: 1.088

6.  Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib.

Authors:  A Zhou; E M Knoche; E K Engle; D A C Fisher; S T Oh
Journal:  Blood Cancer J       Date:  2015-10-02       Impact factor: 11.037

Review 7.  Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature.

Authors:  Gilbert Bader; Bernard Dreiling
Journal:  J Investig Med High Impact Case Rep       Date:  2019 Jan-Dec

8.  Emergence of BCR-ABL1 Chronic Myeloid Leukemia in a JAK2-V617F Polycythemia Vera.

Authors:  Mariana Lorenzo; Sofia Grille; Mariana Stevenazzi
Journal:  J Hematol       Date:  2020-04-23

9.  Two cases of myeloproliferative neoplasm with a concurrent JAK2 (V617F) mutation and BCR/ABL translocation without chronic myelogenous leukemia phenotype acquisition during hydroxyurea treatment.

Authors:  Sang Hyuk Park; Hyun-Sook Chi; Young-Uk Cho; Seongsoo Jang; Chan-Jeoung Park; Dae-Young Kim; Je-Hwan Lee; Kyoo-Hyung Lee
Journal:  Ann Lab Med       Date:  2013-04-17       Impact factor: 3.464

10.  Concomitant essential thrombocythemia with JAK2 V617F mutation in a patient with chronic myeloid leukemia with major molecular response with imatinib and long-term follow-up.

Authors:  Katia Borgia Barbosa Pagnano; Márcia Torresan Delamain; Mariana Munari Magnus; José Vassallo; Carmino Antonio DE Souza; Daiane DE Almeida; Irene Lorand-Metze
Journal:  Oncol Lett       Date:  2016-05-26       Impact factor: 2.967

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.